Clinical Trial News and Research

RSS

Alkem, Karo Bio partner to license eprotirome

Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd.

26 Apr 2011

Dactinomycin more effective for low-risk gestational tumor treatment

A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women.

26 Apr 2011

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

Hypertension is very common among older adults. 64 percent of older men and 78 percent of older women have high blood pressure, placing them at heightened risk for heart disease including heart failure, stroke, coronary artery disease and atrial fibrillation, as well as chronic kidney disease and diabetes mellitus.

26 Apr 2011

Study questions suitability of anti-retroviral drugs for the young

According to a new major study one in eight children born with HIV becomes resistant to the three main classes of drugs used to suppress the virus within five years of starting treatment. This is the first major study that looks at drug resistance in 1,000 European children born with HIV. It raises questions about the suitability of anti-retroviral drugs for the young.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

U-M receives Taubman Institute's $100 million gift for innovative medical science

A. Alfred Taubman has become U-M's largest individual donor, with total giving of more than $142 million. His latest gift of $56 million to the A. Alfred Taubman Medical Research Institute, announced today before the University's Board of Regents, will bring his support of innovative medical science at the University of Michigan to a total of $100 million.

25 Apr 2011

nSpire Health sales increase 3% to $27.6M for 2011

nSpire Health, LLC, a leading provider of respiratory diagnostic devices and clinical trial services, issued audited results for 2010 today. Sales of $27.6M are up 3% year over year. The Company reported a $3.6M improvement in EBIT when compared to 2009 and its highest profit since the founding of the company in 2006. Cash is up $2.4M and debt reduced to less than $400K.

25 Apr 2011

Maxwell Biotech, Sequella enter license agreement to commercialize SQ109 for TB treatment

Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, and Maxwell Biotech Venture Fund announced their agreement to complete the clinical development and commercialize SQ109 for treatment of tuberculosis in the Russian Federation and neighboring Commonwealth of Independent States countries, including Armenia, Azerbaijan, Belorussia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Ukraine.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo Company, Limited, announced today that the company has received its first marketing approval for LIXIANA 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

22 Apr 2011

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

22 Apr 2011

Velos and Comaiba collaborate to provide healthcare risk and compliance management solutions

Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.

22 Apr 2011

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Acupuncture provides long-lasting relief to hot flashes, heart palpitations and anxiety due to side effects of the hormone given to counteract testosterone, the hormone that induces prostate cancer, according to a study published in the April issue of the International Journal of Radiation Oncology-Biology-Physics, an official journal of the American Society for Radiation Oncology.

22 Apr 2011

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

Endologix total revenue increases 28% to $18.5 million for first quarter 2011

Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.

22 Apr 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.

22 Apr 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Clinical Trial News and Research

Alkem, Karo Bio partner to license eprotirome

Dactinomycin more effective for low-risk gestational tumor treatment

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

Study questions suitability of anti-retroviral drugs for the young

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

U-M receives Taubman Institute's $100 million gift for innovative medical science

nSpire Health sales increase 3% to $27.6M for 2011

Maxwell Biotech, Sequella enter license agreement to commercialize SQ109 for TB treatment

Study shows neutralizing antibodies against GM-CSF can halt MS development

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

Velos and Comaiba collaborate to provide healthcare risk and compliance management solutions

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Endologix total revenue increases 28% to $18.5 million for first quarter 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer